Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.5 USD | +2.25% | +3.47% | -16.21% |
Financials (USD)
Sales 2024 * | 538M | Sales 2025 * | 581M | Capitalization | 1.32B |
---|---|---|---|---|---|
Net income 2024 * | -189M | Net income 2025 * | -203M | EV / Sales 2024 * | 2.57 x |
Net Debt 2024 * | 67.93M | Net Debt 2025 * | 234M | EV / Sales 2025 * | 2.67 x |
P/E ratio 2024 * |
-6.96
x | P/E ratio 2025 * |
-6.67
x | Employees | 1,453 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.74% |
Latest transcript on NovoCure Limited
1 day | -0.89% | ||
1 week | +1.49% | ||
Current month | -21.75% | ||
1 month | -7.35% | ||
3 months | -10.66% | ||
6 months | -13.14% | ||
Current year | -18.08% |
Managers | Title | Age | Since |
---|---|---|---|
Asaf Danziger
CEO | Chief Executive Officer | 56 | 01-12-31 |
Ashley Cordova
DFI | Director of Finance/CFO | 45 | 14-05-31 |
Moshe Giladi
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Doyle
CHM | Chairman | 61 | 03-12-31 |
Kin Yip Leung
BRD | Director/Board Member | 62 | 11-08-04 |
David Hung
BRD | Director/Board Member | 66 | 18-05-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.81% | 0 M€ | 0.00% | - | |
0.71% | 0 M€ | 0.00% | - | |
0.19% | 18 M€ | +3.79% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 12.51 | +2.29% | 182 140 |
24-04-25 | 12.23 | -0.89% | 1,152,169 |
24-04-24 | 12.34 | +2.36% | 1,317,018 |
24-04-23 | 12.06 | +1.90% | 839,660 |
24-04-22 | 11.83 | -2.15% | 809,482 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.08% | 1.32B | |
+72.64% | 12.34B | |
-18.30% | 7.96B | |
+15.38% | 7.16B | |
+5.08% | 5.72B | |
+6.51% | 5.03B | |
+21.99% | 4.35B | |
-21.67% | 3.99B | |
-41.36% | 2.21B | |
+0.37% | 2.01B |
- Stock Market
- Equities
- NVCR Stock